Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine - RP Scherer

Next Previous
X
Search
Drug Profile

Apomorphine - RP Scherer

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RP Scherer
  • Developer Orion; RP Scherer
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 20 Oct 2003 Orion has terminated research of apomorphine and seeks to outlicense the agent
  • 15 Mar 2002 Phase-III clinical trials in Parkinson's disease in Europe (PO)
  • 15 Mar 2002 The fast-dissolving tablet formulation of apomorphine has received orphan drug status in Europe for the treatment of off-periods in patients with Parkinson's disease who are not responding to other oral medications

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top